Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 8/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580733 | 0.87 | CTSK (0.52) | UTS2RCTSK | |
| SCHEMBL6580365 | 0.86 | UTS2R (0.55) | UTS2RCTSKCASP1CASP3DRD3 | |
| SCHEMBL6580354 | 0.85 | CTSK (0.63) | UTS2RCTSK | |
| SCHEMBL6577864 | 0.84 | CTSK (0.52) | UTS2RCTSKCASP1CASP3 | |
| SCHEMBL6578490 | 0.83 | CTSK (0.48) | UTS2RCTSKCASP1CASP3 | |
| SCHEMBL6578056 | 0.82 | TAS1R3 (0.54) | UTS2RCTSKCASP1CASP3DRD3 | |
| SCHEMBL6578322 | 0.82 | CTSK (0.52) | UTS2RCTSKCASP1CASP3 | |
| SCHEMBL6580255 | 0.79 | CTSK (0.46) | UTS2RCTSKCASP1CASP3KCNH2 | |
| SCHEMBL6580377 | 0.78 | UTS2R (0.54) | UTS2RCTSKCASP1CASP3KCNH2 | |
| SCHEMBL7410404 | 0.78 | UTS2R (0.62) | UTS2RDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | claimed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | claimed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | claimed |
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | UTS2R 1950/4885CTSK 1/4885CASP1 131/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | UTS2R 972/4885CTSK 100/4885CASP1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.